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Abstract 
Purpose: To synthesis and characterize some novel isatin-incorporated thiadiazoles and screen them 
for anti-breast cancer activity in human breast adenocarcinoma cells (MCF-7). 
Method: A series of isatin incorporated Schiff bases of thiadiazoles (3a-3l) was synthesized by reaction 
of substituted thiadiazoles (1a-1d) with isatin (2a) and N-alkyl substituted isatin (2b-2c) and 
characterized by elemental analysis, IR, 1H NMR, 13C NMR and LCMS. The newly synthesized 
compounds were screened for their in-vitro cytotoxicity against MCF-7 cell lines by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric and Sulforhodamine B (SRB) 
methods. 
Results: Compounds 3a, 3c, 3d, 3g and 3j showed anticancer activity in both MTT and SRB assay. 
Compound 3-(5-(4-chlorophenyl)-1,3,4-thiadiazol-2-ylimino)-1-ethylindolin-2-one (3g) showed most 
potent cytotoxic activity against MCF-7 cell lines.  
Conclusion: The novel isatin incorporated thiadiazoles synthesized and characterized in this study 
possess anti-cancer activities in human breast adenocarcinoma cells (MCF-7). This can possibly lead to 
emergence of new anti-breast cancer agents. 
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After cardio-vascular diseases, cancer is the 
second major cause of mortality in the world and 
accounting for 8.2 million deaths in 2012. 
Furthermore, breast cancer is a most common 
form of invasive cancer in women throughout the 
world and remains the most frequent cause of 
malignancy associated deaths among women. 
The effective treatment of this disease is 
restricted due to the development of breast 
cancer resistance against chemotherapy and 
endocrine therapy [1-3].  At the same time, isatin 
derivatives have also been reported as cytotoxic 
agents [4,5]. Some of the isatin incorporated 
thiazolines and benzthiazoles have shown 
significant anti breast cancer activity [6,7]. 
Therefore, there is essential to search and 
develop novel and potent chemotherapeutic 
agents that could overcome this health problem. 
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Thiadiazole, a promising heterocyclic template 
that has versatile pharmacological activity 
constitutes major class of agents for 
development of novel drugs. Numerous studies 
demonstrated that thiadiazole scaffold shows 
anticancer activity against various tumor cell 
lines [8-10]. Various reports suggested that 
various substituted thiadiazole derivatives 
exhibited significant anticancer activity against 
MCF-7 cell lines [11-13].  
 
In this work, the objective was to incorporate 
isatins to thiadiazole moiety by using 
pharmacophore hybridization approach as it was 
expected that these two active anticancer 






Human breast adenocarcinoma cells (MCF-7) 
were purchased from NCCS Pune (India). MTT 
reagent, 10 % foetal bovine serum (FBS), 
Dulbacco’s minimum essential medium (DMEM) 
media and sulphorhodamine solution were 
purchased from Sigma Aldrich (USA). 
Antimycotic solution and TPVG solution were 
obtained from Himedia. Tissue culture flasks, 96 
well microculture plates obtained from Tarson 
and Nunc (USA). All analytical grade reagents 
and solvents were purchased from Merck 
Chemical Co (Germany) and dried in a 




Synthesis of 2-amino-5-aryl-1,3,4-thiadiazoles 
(1a-1d) 
 
The thiosemicarbazide (0.1 mol) was added in 
aryl carboxylic acid (0.1 mol) in an equipped 
assembly with a stirring bar. The reaction mixture 
was poured slowly over 0.5 h to polyphosphoric 
acid (10 times the weight of carboxylic acid) at 
80-90 °C with stirring. The reaction mixture was 
stirred at 80-90 °C for 2-4 h and then cooled to 
room temperature; further water/ice was added. 
Finally, the mixture was made alkaline by NH3 
(0.88 g/ml), filtered and dried. The desired 
product was eluted from EtOH and purified by 





Equimolar quantities of an appropriate 2-amino-
5-aryl-1,3,4-thiadiazoles (1a-1d) and isatins (2a-
2c) (0.001 mol each) were dissolved in absolute 
ethanol (15 ml). Further, glacial acetic acid (0.2 
ml) was added to the reaction mixture with 
continuous stirring. The reaction mixture was 
refluxed for 10-12 h with stirring, concentrated 
under reduced pressure to remove absolute 
ethanol and acetic acid and leave the mixture to 
cool at room temperature. The crude solid 
mixture was filtered and eluted from ethanol (70 
%) to furnish 3a-3l (Figure 1). 
 
Characterization of synthesized compounds 
 
All the reactions were followed by thin layer 
chromatography (TLC) analysis which performed 
on silica gel G for TLC (Merck) and visualized 
with iodine vapour. Melting points (ºC) were 
determined in open capillary tubes and were 
uncorrected. Infra-red absorption spectra were 
recorded on Jasco FT/IR-470 PLUS (Japan), KBr 
diffuse reflectance (υmax in cm-1). The 1H and 13C 
chemical shifts were recorded on the field 
strength 400 and 100 MHz  specified by Bruker 
DPX-400 instrument, England and measured as 
parts per million (ppm) downfield from TMS 
(Me4Si). The LCMS of the synthesized 
compounds were recorded on Shimadzu 8201PC 
spectrometer, Japan. IR, 1H NMR, 13C NMR and 
LCMS were consistent with the proposed 
structures. Elemental analysis was done on a 
CHN rapid analyzer and showed satisfactory 
results within ± 0.4 % of the theoretical values. 
 
Determination of in-vitro cytotoxic activity 
 
The isatin incorporated thiadiazoles (3a-3l) were 
screened for in vitro cytotoxicity against MCF-7 
cell lines by MTT and SRB models. 
 
Maintenance of cell lines 
 
MCF-7 cells were grown in 75 cm2 tissue culture 
flasks containing DMEM media supplemented 
with 10 % FBS, TPVG solution at 37 ºC in CO2 
incubator in an atmosphere of humidified 95 % 
air and 5 % CO2. Further, they were maintained 




The MTT was reduced to a colored product due 
to activity of NAD (P) H-dependent 
deshydrogenases enzyme. It indicates the level 
of energy metabolism in cells. The cells were 
seeded in 96-well microplates in DMEM medium 
supplemented (0.1 ml) with FBS (10 %). These 
cells were cultured routinely in a humidified 
incubator in 5 % CO2 at 37 C for 24 h. Test 
compounds were added in various 
concentrations (5-25 μg/ml) and further 
incubated for 24 h.  
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Figure 1: Reaction scheme for the synthesis of 3a-3l: (i) Polyphosphoric acid; (ii) EtOH, CH3COOH 
 
The medium was discarded, tetrazolium dye 
(MTT) solution (0.1 ml, 1 mg/ml in PBS) was 
added to every well and re-incubated for 4 h. The 
formazan crystals formed was dissolved by 
adding of 0.1 ml DMSO. The plate was then read 




Cell suspension (0.1 ml) of optimum density was 
added into each well of 96-well plates. Various 
concentrations (5-25 μg/ml) of test compounds 
were made in the culture medium. Each 
concentration of test compounds (0.1 ml) was 
added to the wells containing the cells and 0.1 ml 
of medium only to the control wells. Then these 
cells were incubated with the test compounds for 
48 h and fixed with ice-cold trichloroacetic acid 
(TCA) at 4 °C for 1 h. Then these plates were 
washed 5 times in water and dried in the air. 
Further SRB solution (0.05 ml) was added to 
each well of the dried 96-well plates and kept for 
staining at room temperature for half an hour. 
Then SRB solution was removed by washing the 
plates with acetic acid (1 % v/v) 5 times to 
remove dye. Bound SRB was solubilized using 
unbuffered Tris Base (0.1 ml, 10 mM, pH 10.5) to 
each well and shaked for 5 min. Plates were read 
using a 96-well plate reader at the working 






The following compounds were successfully 
synthesized: 
 
5-phenyl-1,3,4-thiadiazol-2-amine (1a). Yield, 65 
%; mp 226-228°C. IR υmax/cm-1 3488 (NH), 3074 
(Aromatic C–H), 1596 (C=N). 1H NMR (400 MHz, 
DMSO-d6); δ: 7.26–7.59 (m, 5H, Ar-H), 5.13 (s, 
2H, NH2). 13C NMR (100 MHz, DMSO-d6): δ: 
172.1 (C2), 167.9 (C5), 133.7 (C1-Ar), 131.7 (C4-
Ar), 129.4 (C3,5-Ar), 126.7 (C2,6-Ar). LCMS m/z; 
177.2, [M+1]+. Anal. Calcd for C8H7N3S (%): C, 
54.22; H, 3.98; N, 23.71. Found: C, 54.34; H, 
4.02; N, 23.54. 
 
5-(3,5-dinitrophenyl)-1,3,4-thiadiazol-2-amine 
(1b). Yield, 62 %; mp 242-246°C. IR υmax/cm-1 
3488 (NH), 3058 (Aromatic C–H), 1607 (C=N), 
1469 (C-NO2). 1H NMR (400 MHz, DMSO-d6); δ: 
7.69-7.86 (m, 3H, Ar-H), 6.13 (s, 2H, NH2). 13C 
NMR (100 MHz, DMSO-d6): 171.6 (C2), 163.2 
(C5), 136.4 (C3,5-Ar), 135.7 (C1-Ar), 129.5 (C2,6-
Ar), 119.7 (C4-Ar). LCMS m/z; 267.1, [M+1]+. 
Anal. Calcd for C8H5N5O4S (%): C, 35.96; H, 




Yield, 72 %; mp 230-234°C. IR υmax/cm-1 3471 
(NH), 3064 (Aromatic C–H), 1611 (C=N), 821 (C-
Cl). 1H NMR (400 MHz, DMSO-d6); δ: 6.99-7.38 
(m, 4H, ArH), 3.64 (s, 2H, NH2). 13C NMR (100 
MHz, DMSO-d6): δ: 174.2 (C2), 163.7 (C5), 134.3 
(C1-Ar), 132.8 (C4-Ar), 128.3 (C3,5-Ar), 125.7 
(C2,6-Ar). LCMS m/z; 211.1, [M+1]+. Anal. Calcd 
for C8H6ClN3S (%): C, 45.39; H, 2.86; N, 19.85. 
Found: C, 45.53; H, 2.79; N, 19.97. 
 
5-(4-nitrophenyl)-1,3,4-thiadiazol-2-amine (1d). 
Yield, 69 %; mp 228-232°C. IR υmax/cm-1 3463 
(NH), 3053 (Aromatic C–H), 1619 (C=N), 1452 
(C-NO2). 1H NMR (400 MHz, DMSO-d6); δ: 7.53-
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7.69 (m, 3H, Ar-H), 5.92 (s, 2H, NH2).13C NMR 
(100 MHz, DMSO-d6): δ: 173.8 (C2), 164.3 (C5), 
143.3 (C4-Ar), 137.8 (C1-Ar), 126.6 (C2,6-Ar), 
125.2 (C3,5-Ar).LCMS m/z;222.0, [M+1]+. Anal. 
Calcd for C8H6N4O2S (%): C, 43.24; H, 2.72; N, 
25.21. Found: C, 43.43; H, 2.59; N, 25.28. 
 
3-(5-phenyl-1,3,4-thiadiazol-2-ylimino)indolin-2-
one (3a). Yield, 79 %; mp 232-236 °C. IR 
υmax/cm-1 3476 (NH), 3069 (Aromatic C–H), 1711 
(C=O), 1608, 1586 (C=N). 1H NMR (400 MHz, 
DMSO-d6); δ: 8.32 (s, 1H, NH), 6.83-7.58 (m, 9H, 
Ar). 13C NMR (100 MHz, DMSO-d6): δ: 174.4 (C5-
thia), 169.4 (C2), 167.5 (C2-thia), 149.4 (C3), 
145.9 (C8), 135.7 (C1-Ar), 134.7 (C5), 132.9 (C4-
Ar), 129.0 (C3,5-Ar), 126.8 (C4), 125.6 (C2,6-Ar), 
124.1(C6), 119.7 (C9), 116.2 (C7). LCMS m/z; 
306.1, [M+1]+. Anal. Calcd for C16H10N4OS (%): 
C, 62.73; H, 3.29; N, 18.29. Found: C, 62.56; H, 
3.42; N, 18.42. 
 
3-(5-(3,5-dinitrophenyl)-1,3,4thiadiazol-2-
ylimino)indolin-2-one (3b). Yield, 71 %; mp 282-
284 °C. IR  υmax/cm-1 3462 (NH), 3077 (Aromatic 
C–H), 1694 (C=O), 1619, 1594 (C=N), 1482 (C-
NO2). 1H NMR (400 MHz, DMSO-d6); δ: 8.43 (s, 
1H, NH), 6.96-7.71 (m, 7H, Ar). 13C NMR (100 
MHz, DMSO-d6): δ: 172.6 (C5-thia), 168.2 (C2), 
166.3 (C2-thia), 149.5 (C3), 146.6 (C3,5-Ar), 144.5 
(C8), 135.6 (C1-Ar), 132.7 (C6), 126.2 (C2,6-Ar), 
125.1 (C4), 123.3 (C5), 117.8 (C9), 117.6 (C4-Ar), 
115.8 (C7). LCMS m/z; 396.0, [M+1]+. Anal. 
Calcd for C16H8N6O5S (%): C, 48.49; H, 2.03; N, 
21.20. Found: C, 48.33; H, 2.09; N, 21.32. 
 
3-(5-(4-chlorophenyl)-1,3,4-thiadiazol-2-
ylimino)indolin-2-one (3c). Yield, 74 %; mp 258-
262°C. IR υmax/cm-1 3484 (NH), 3082 (Aromatic 
C–H), 1723 (C=O), 1611, 1590 (C=N), 819 (C-
Cl). 1H NMR (400 MHz, DMSO-d6); 8.38 (s, 1H, 
NH), 7.03-7.52 (m, 8H, Ar). 13C NMR (100 MHz, 
DMSO-d6): δ: 171.4 (C5-thia), 167.5 (C2), 166.1 
(C2-thia), 148.8 (C3), 144.6 (C8), 136.4 (C4-Ar), 
133.8 (C1-Ar), 132.9 (C6), 129.1 (C3,5-Ar), 127.3 
(C2,6-Ar), 125.8 (C4), 123.3 (C5), 117.9 (C9), 
113.2  (C7). LCMS m/z; 341.1, [M+1]+. Anal. 
Calcd for C16H9ClN4OS (%): C, 56.39; H, 2.66; N, 
16.44.Found: C, 56.56; H, 2.72; N, 16.48. 
 
3-(5-(4-nitrophenyl)-1,3,4-thiadiazol-2-
ylimino)indolin-2-one (3d). Yield, 69 %; mp 268-
272°C. IR υmax/cm-1 3475 (NH), 3063 (Aromatic 
C–H), 1698 (C=O), 1616, 1599 (C=N), 1466 (C-
NO2). 1H NMR (400 MHz, DMSO-d6); δ: 8.41 (s, 
1H, NH), 6.89-7.62 (m, 8H, Ar). 13C NMR (100 
MHz, DMSO-d6): δ: 172.1 (C5-thia), 168.2 (C2), 
166.5 (C2-thia), 148.5 (C3), 147.4(C4-Ar) , 143.9 
(C8), 139.7 (C1-Ar), 132.9 (C6), 126.8 (C2,6-Ar), 
125.4 (C4), 124.3 (C3,5-Ar), 123.3 (C5), 117.8 
(C9), 113.7 (C7). LCMS m/z; 352.1, [M+1]+. Anal. 
Calcd for C16H9N5O3S (%): C, 54.70; H, 2.58; N, 
19.93. Found: C, 54.82; H, 2.73; N, 19.71. 
 
1-ethyl-3-(5-phenyl-1,3,4-thiadiazol-2-
ylimino)indolin-2-one (3e). Yield, 72 %; mp 224-
226°C. IR υmax/cm-1 3081 (Aromatic C–H), 1718 
(C=O), 1612, 1586 (C=N), 1349 (C-N). 1H NMR 
(400 MHz, DMSO-d6); δ: 6.97-7.52 (m, 9H, Ar), 
3.58-3.62 (q, 2H, CH2), 1.29-1.31 (t, 3H, CH3). 
13C NMR (100 MHz, DMSO-d6): δ: 170.7 (C5-
thia), 167.4 (C2), 165.8 (C2-thia), 153.3 (C3), 
146.6 (C8), 133.7 (C1-Ar), 133.6 (C6), 132.0 (C4-
Ar), 129.2 (C3,5-Ar), 128.4 (C4), 126.8 (C2,6-Ar), 
123.4 (C5), 117.3 (C9), 113.3 (C7), 39.3 (-CH2-), 
18.5 (-CH3). LCMS m/z; 335.1, [M+1]+. Anal. 
Calcd for C18H14N4OS (%): C, 64.65; H, 4.22; N, 
16.75. Found: C, 64.83; H, 4.27; N, 16.62. 
 
1-ethyl-3-(5-(3,5-dinitrophenyl)-1,3,4thiadiazol-2-
ylimino)indolin-2-one (3f). Yield, 78 %; mp 208-
212°C. IR υmax/cm-1 3076 (Aromatic C–H), 1705 
(C=O), 1608, 1592 (C=N), 1474 (C-NO2), 1352 
(C-N). 1H NMR (400 MHz, DMSO-d6); δ: 6.73-
7.77 (m, 7H, Ar), 3.63-3.66 (q, 2H, CH2), 1.32-
1.35 (t, 3H, CH3). 13C NMR (100 MHz, DMSO-
d6): δ: 172.4 (C5-thia), 167.7 (C2), 166.7 (C2-thia), 
152.7 (C3), 147.5 (C8), 146.7 (C3,5-Ar), 136.2 (C1-
Ar), 134.3 (C6), 125.5 (C4), 124.9 (C2,6-Ar), 124.6 
(C5), 119.2 (C4-Ar), 118.6 (C9), 114.3 (C7), 40.6 (-
CH2-), 19.4 (-CH3). LCMS m/z; 425.1, [M+1]+. 
Anal. Calcd for C18H12N6O5S (%): C, 50.94; H, 




1-ethylindolin-2-one (3g). Yield, 70 %; mp 242-
246°C. IR υmax/cm-1 3058 (Aromatic C–H), 1687 
(C=O), 1623, 1597 (C=N), 1343 (C-N), 824 (C-
Cl). 1H NMR (400 MHz, DMSO-d6); δ: 7.06-7.65 
(m, 8H, Ar), 3.57-3.60 (q, 2H, CH2), 1.30-1.33 (t, 
3H, CH3). 13C NMR (100 MHz, DMSO-d6): δ: 
170.8 (C5-thia), 166.7 (C2), 162.2 (C2-thia), 155.3 
(C3), 146.7 (C8), 136.5 (C4-Ar), 132.2 (C1-Ar), 
131.6 (C6), 129.1 (C3,5-Ar), 127.2 (C2,6-Ar), 124.4 
(C4), 121.6 (C5), 116.8 (C9), 113.5 (C7), 41.3 (-
CH2-), 17.5 (-CH3). LCMS m/z; 368.2, [M+1]+. 
Anal. Calcd for C18H13ClN4OS (%): C, 58.61; H, 




ylimino)indolin-2-one (3h). Yield, 75 %; mp 272-
274°C. IR υmax/cm-1 3065 (Aromatic C–H), 1723 
(C=O), 1611, 1596 (C=N), 1478 (C-NO2), 1338 
(C-N). 1H NMR (400 MHz, DMSO-d6); δ: 6.83-
7.68 (m, 8H, Ar), 3.61-3.65 (q, 2H, CH2), 1.27-
1.30 (t, 3H, CH3). 13C NMR (100 MHz, DMSO-
d6): δ: 172.4 (C5-thia), 167.2 (C2), 163.8 (C2-thia), 
153.5 (C3), 147.4 (C4-Ar), 144.3 (C8), 137.5 (C1-
Ar), 130.6 (C6), 129.3 (C4), 126.3 (C2,6-Ar), 124.7 
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(C3,5-Ar), 123.4 (C5), 120.3 (C9), 113.5(C7), 42.3 
(-CH2-), 18.5 (-CH3). LCMS m/z; 380.2, [M+1]+. 
Anal. Calcd for C18H13N5O3S (%): C, 56.98; H, 




ylimino)indolin-2-one (3i). Yield, 73 %; mp 288-
292°C. IR υmax/cm-1 3087 (Aromatic C–H), 1709 
(C=O), 1619, 1588 (C=N), 1346 (C-N). 1H NMR 
(400 MHz, DMSO-d6); δ: 6.67-7.72 (m, 14H, Ar), 
4.29-4.33 (d, 2H, CH2). 13C NMR (100 MHz, 
DMSO-d6): δ: 171.1 (C5-thia), 167.4 (C2), 164.2 
(C2-thia), 152.3 (C3), 146.6 (C8), 136.0 (C1-Ar2), 
132.6 (C1-Ar1), 133.1 (C6), 131.7 (C4-Ar1), 128.0 
(C3,5-Ar1), 125.6 (C3,5-Ar2), 123.3 (C2,6-Ar2), 121.1 
(C4-Ar2), 118.1 (C4), 118.8 (C2,6-Ar1), 116.3 (C5), 
115.9 (C9), 113.0 (C7), 50.13 (-CH2-). LCMS m/z; 
397.1, [M+1]+. Anal. Calcd for C23H16N4OS (%): 
C, 69.68; H, 4.07; N, 14.13. Found: C, 69.82; H, 
4.15; N, 14.23. 
 
1-benzyl-3-(5-(3,5-dinitrophenyl)-1,3,4-thiadiazol-
2-ylimino)indolin-2-one (3j). Yield, 76 %; mp 320-
324°C. IR υmax/cm-1 3081 (Aromatic C–H), 1693 
(C=O), 1609, 1573 (C=N), 1471 (C-NO2), 1359 
(C-N). 1H NMR (400 MHz, DMSO-d6); δ: 6.83-
7.89 (m, 12H, Ar), 4.29-4.33 (d, 2H, CH2). 13C 
NMR (100 MHz, DMSO-d6): δ: 171.4 (C5-thia), 
168.6 (C2), 163.2 (C2-thia), 155.3 (C3), 147.5 
(C3,5-Ar1), 141.6 (C8), 138.0 (C1-Ar2), 133.2 (C1-
Ar1), 133.3 (C6), 126.6 (C3,5-Ar2), 125.3 (C2,6-Ar2), 
126.1 (C4-Ar2), 123.2 (C2,6-Ar1), 121.1 (C4), 120.3 
(C5), 117.0 (C4-Ar1), 115.1 (C9), 111.0 (C7), 52.3 
(-CH2-). LCMS m/z; 486.4, [M+1]+. Anal. Calcd 
for C23H14N6O5S (%): C, 56.79; H, 2.90; N, 17.28. 
Found: C, 56.69; H, 2.98; N, 17.38. 
 
1-benzyl-3-(5-(4-chlorophenyl)-1,3,4-thiadiazol-2-
ylimino)indolin-2-one (3k). Yield, 73 %; mp 262-
264°C. IR  υmax/cm-1 3079 (Aromatic C–H), 1713 
(C=O), 1614, 1574 (C=N), 1352 (C-N), 816 (C-
Cl). 1H NMR (400 MHz, DMSO-d6); δ: 6.92-7.72 
(m, 13H, Ar), 4.29-4.33 (d, 2H, CH2). 13C NMR 
(100 MHz, DMSO-d6): δ: 170.9 (C5-thia), 167.4 
(C2), 164.2 (C2-thia), 154.3 (C3), 147.6 (C8), 
139.1 (C1-Ar2), 136.6 (C4-Ar1), 131.2 (C1-Ar1), 
129.5 (C6), 126.1 (C3,5-Ar1), 123.6 (C3,5-Ar2), 
121.3 (C2,6-Ar2), 120.0 (C4-Ar2), 118.5 (C2,6-Ar1), 
112.1 (C4), 111.3 (C5), 110.7 (C9), 107.0 (C7), 
56.3 (-CH2-). LCMS m/z; 431.1, [M+1]+. Anal. 
Calcd for C23H15ClN4OS (%): C, 64.11; H, 3.51; 
N, 13.00. Found: C, 64.24; H, 3.62; N, 12.89. 
 
1-benzyl-3-(5-(4-nitrophenyl)-1,3,4-thiadiazol-2-
ylimino)indolin-2-one (3l). Yield, 77 %; mp 294-
296°C. IR υmax/cm-1 3068 (Aromatic C–H), 1722 
(C=O), 1619, 1589  (C=N), 1484 (C-NO2), 1361 
(C-N). 1H NMR (400 MHz, DMSO-d6); δ: 6.71-
7.81 (m, 13H, Ar), 4.29-4.33 (d, 2H, CH2). 13C 
NMR (100 MHz, DMSO-d6): δ: 171.0 (C5-thia), 
166.2 (C2), 163.2 (C2-thia), 157.3 (C3), 148.1 (C4-
Ar1), 142.6 (C8), 139.5 (C4-Ar1), 137.0 (C1-Ar2), 
133.1 (C6), 128.7 (C3,5-Ar2), 126.3 (C2,6-Ar2), 
122.1 (C4-Ar2), 120.7 (C2,6-Ar1), 118.4 (C4), 115.7 
(C3,5-Ar1), 111.3 (C5), 106.9 (C9), 102.0 (C7), 
53.13 (-CH2-). LCMS m/z; 441.1, [M+1]+. Anal. 
Calcd for C23H15N5O3S (%): C, 62.43; H, 3.51; N, 
15.94. Found: C, 69.59; H, 4.33. 
 
Of the 12 compounds synthesized, five 
compounds (3a, 3c, 3d, 3g and 3j) of the 1-alkyl-
3-(5-aryl-1,3,4-thiadiazol-2-ylimino)indolin-2-ones 
(3a-3l) significantly decreased MCF-7 cell 
viability produced cytotoxic activity (IC50 for MCF-
7 by MTT assay of 12,62-21.41μg/ml, Table 1). 
 
Table 1: In vitro cytotoxic activity of isatin incorporated 
Schiff bases of thiadiazoles (3a-3l) against MCF-7 
 
Compound IC50 (μg/ml) 
MTT assay SRB assay 
3a 13.72 ± 0.1058 16.41± 0.4179 
3b - - 
3c 12.62± 0.2586 15.14± 0.3925 
3d 16.37± 0.3805 18.44± 0.5196 
3e - - 
3f - - 
3g 10.46± 0.1637 13.04± 0.3435 
3h - - 
3i - - 
3j 21.41± 0.4676 24.27± 0.2464 
3k - - 
3l - - 
The results represent mean ± SEM of three 
independent experiments. IC50values were obtained 
using a dose response curve by non-linear regression 
using a curve fitting program, Graph Pad Prism 5.0. 




In this work, 12 novel isatin incorporated 
thiadiazoles have successfully been synthesized 
and characterised. Five of the compounds 
demonstrated cytotoxic effects. In the synthetic 
procedure, thiosemicarbazide was reacted with 
substituted aromatic carboxylic acid in the 
presence of polyphosphoric acid to yield 2-
amino-5-aryl-1,3,4-thiadiazoles (1a-1d). The 
proposed structures of these compounds were 
confirmed on the basis of spectroscopic data (IR 
and NMR) and elemental analysis. The IR 
spectra showed C=N absorption bands at 1619-
1596 cm-1. 
 
In the last step, 2-amino-5-aryl-1,3,4-thiadiazoles 
(1a-1d) were reacted with isatin (2a) and N-alkyl 
substituted isatin (2b-2c) to formation of isatin 
incorporated Schiff bases of thiadiazoles (3a-3l). 
The proposed structures of (3a-3l) were 
confirmed by spectroscopic data (IR, 1H and 13C 
Kumar et al 
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NMR) and elemental analysis and data are 
shown in experimental protocol section. The 
structures of compounds 3a-3l were confirmed 
by the disappearance of NH2 peak in 1H NMR 
spectra. The remaining protons appeared at the 
expected chemical shifts. 
 
From the structure-activity relationship (SAR) 
study, it was found that the substitution at C-5 
position of the 1,3,4-thiadiazole ring  may affect 
the cytotoxic activity to the compounds. The 
compound 3c and 3g, possessing a 4-
chlorophenyl ring at C-5 position, were found to 
be most active compounds. Replacement of 4-
chloro with 4-nitro or 3,5-dinitro decreased 
cytotoxicity against MCF-7 cell lines. Compound 
3-(5-(4-chlorophenyl)-1,3,4-thiadiazol-2-ylimino)-
1-ethylindolin-2-one (3g) showed highest 
potency with IC50 10.46 and 13.04 μg/ml in MTT 





A novel and simple method for the synthesis of 
isatin incorporated Schiff bases of thiadiazoles 
has been developed. Some of the synthesized 
compounds produced cytotoxic activity against 
MCF-7 cells; in particular, the compounds 3-(5-
phenyl-1,3,4-thiadiazol-2-ylimino)indolin-2-one 
(3a), 3-(5-(4-chlorophenyl)-1,3,4-thiadiazol-2-
ylimino)indolin-2-one (3c) and 3-(5-(4-chloro-
phenyl)-1,3,4-thiadiazol-2-ylimino)-1-ethylindolin-
2-one (3g) were found as promising compounds 
and could serve as leads for further modification 
to develop clinically useful anticancer agents. 
These new findings might be useful for scientist 
in future research and development of isatin 
incorporated thiadiazoles nucleus as newer anti-
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